Roseola: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}:{{AE}}{{DAMI}} | {{CMG}}:{{AE}}{{DAMI}} | ||
{{SK}} | {{SK}} Roseola infantum, Exanthem subitum, sixth disease, 3- day rash. | ||
==[[Roseola overview|Overview]]== | ==[[Roseola overview|Overview]]== | ||
Roseola is characterized by an abrupt rise in body temperature to as high as 40°C followed by a rapid drop to normal within the next 2–4 days which coincides with the appearance of an erythematous maculopapular skin rash that persists for 1–3 days | |||
==[[Roseola historical perspective|Historical Perspective]]== | ==[[Roseola historical perspective|Historical Perspective]]== | ||
Human herpes virus which is the causative viral agent of roseola was first identified in | |||
==[[Roseola classification|Classification]]== | ==[[Roseola classification|Classification]]== | ||
Revision as of 14:11, 25 May 2017
|
Roseola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Roseola On the Web |
|
American Roentgen Ray Society Images of Roseola |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]
Synonyms and keywords: Roseola infantum, Exanthem subitum, sixth disease, 3- day rash.
Overview
Roseola is characterized by an abrupt rise in body temperature to as high as 40°C followed by a rapid drop to normal within the next 2–4 days which coincides with the appearance of an erythematous maculopapular skin rash that persists for 1–3 days
Historical Perspective
Human herpes virus which is the causative viral agent of roseola was first identified in
Classification
Pathophysiology
Causes
Differentiating Any Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies